Cargando…

Development and Implementation of an Internal Quality Control Sample to Standardize Oligomer-Based Diagnostics of Alzheimer’s Disease

Protein misfolding and aggregation are pathological hallmarks of various neurodegenerative diseases. In Alzheimer’s disease (AD), soluble and toxic amyloid-β (Aβ) oligomers are biomarker candidates for diagnostics and drug development. However, accurate quantification of Aβ oligomers in bodily fluid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pils, Marlene, Dybala, Alexandra, Rehn, Fabian, Blömeke, Lara, Bujnicki, Tuyen, Kraemer-Schulien, Victoria, Hoyer, Wolfgang, Riesner, Detlev, Willbold, Dieter, Bannach, Oliver
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217173/ https://www.ncbi.nlm.nih.gov/pubmed/37238187 http://dx.doi.org/10.3390/diagnostics13101702

Ejemplares similares

Quantitative detection of α-Synuclein and Tau oligomers and other aggregates by digital single particle counting
por: Blömeke, Lara, et al.
Publicado: (2022)

Aβ oligomer concentration in mouse and human brain and its drug-induced reduction ex vivo
por: Kass, Bettina, et al.
Publicado: (2022)

Oral treatment with the all-d-peptide RD2 enhances cognition in aged beagle dogs – A model of sporadic Alzheimer’s disease
por: Kutzsche, Janine, et al.
Publicado: (2023)

Patients with isolated REM-sleep behavior disorder have elevated levels of alpha-synuclein aggregates in stool
por: Schaffrath, Anja, et al.
Publicado: (2023)

Tau protein aggregation associated with SARS-CoV-2 main protease
por: Eberle, Raphael Josef, et al.
Publicado: (2023)

Application of an Amyloid Beta Oligomer Standard in the sFIDA Assay
por: Kühbach, Katja, et al.
Publicado: (2016)

Seeded Fibrillation as Molecular Basis of the Species Barrier in Human Prion Diseases
por: Luers, Lars, et al.
Publicado: (2013)

Aβ Oligomer Elimination Restores Cognition in Transgenic Alzheimer’s Mice with Full-blown Pathology
por: Schemmert, Sarah, et al.
Publicado: (2018)

Detection of Prion Protein Particles in Blood Plasma of Scrapie Infected Sheep
por: Bannach, Oliver, et al.
Publicado: (2012)

Structural details of amyloid β oligomers in complex with human prion protein as revealed by solid-state MAS NMR spectroscopy
por: König, Anna S., et al.
Publicado: (2021)

Molecular Interactions between Prions as Seeds and Recombinant Prion Proteins as Substrates Resemble the Biological Interspecies Barrier In Vitro
por: Panza, Giannantonio, et al.
Publicado: (2010)

Origin of metastable oligomers and their effects on amyloid fibril self-assembly
por: Hasecke, Filip, et al.
Publicado: (2018)

Viroid research and its significance for RNA technology and basic biochemistry
por: Steger, Gerhard, et al.
Publicado: (2018)

Amyloid oligomers as on-pathway precursors or off-pathway competitors of fibrils
por: Muschol, Martin, et al.
Publicado: (2023)

EGFP oligomers as natural fluorescence and hydrodynamic standards
por: Vámosi, György, et al.
Publicado: (2016)

Alzheimer’s Disease, Oligomers, and Inflammation
por: Forloni, Gianluigi, et al.
Publicado: (2018)

Peptides for Therapy and Diagnosis of Alzheimer’s Disease
por: Funke, Susanne Aileen, et al.
Publicado: (2012)

QIAD assay for quantitating a compound’s efficacy in elimination of toxic Aβ oligomers
por: Brener, Oleksandr, et al.
Publicado: (2015)

Aβ42 pentamers/hexamers are the smallest detectable oligomers in solution
por: Wolff, Martin, et al.
Publicado: (2017)

Do We Need Anti-Prionic Compounds to Treat Alzheimer’s Disease?
por: Willbold, Dieter, et al.
Publicado: (2019)

Stabilization of Monomeric Tau Protein by All D-Enantiomeric Peptide Ligands as Therapeutic Strategy for Alzheimer’s Disease and Other Tauopathies
por: Altendorf, Tim, et al.
Publicado: (2023)

Amyloid β-protein oligomers and Alzheimer’s disease
por: Hayden, Eric Y, et al.
Publicado: (2013)

β-Amyloid oligomers in aging and Alzheimer’s disease
por: Zahs, Kathleen R., et al.
Publicado: (2013)

Tau oligomers in cerebrospinal fluid in Alzheimer's disease
por: Sengupta, Urmi, et al.
Publicado: (2017)

Optimization of the All-D Peptide D3 for Aβ Oligomer Elimination
por: Klein, Antonia Nicole, et al.
Publicado: (2016)

Tau Oligomers: The Toxic Player at Synapses in Alzheimer’s Disease
por: Guerrero-Muñoz, Marcos J., et al.
Publicado: (2015)

Environmental Factors Preceding Aβ40 Monomer to Oligomers and the Detection of Oligomers in Alzheimer's Disease Patient Serum
por: Matsunaga, Yoichi, et al.
Publicado: (2012)

β-Hairpin of Islet Amyloid Polypeptide Bound to an Aggregation Inhibitor
por: Mirecka, Ewa A., et al.
Publicado: (2016)

Molecular Features and Metal Ions That Influence 10-23 DNAzyme Activity
por: Rosenbach, Hannah, et al.
Publicado: (2020)

Clustering of human prion protein and α-synuclein oligomers requires the prion protein N-terminus
por: Rösener, Nadine S., et al.
Publicado: (2020)

Metabolic resistance of the D-peptide RD2 developed for direct elimination of amyloid-β oligomers
por: Elfgen, Anne, et al.
Publicado: (2019)

Tau Oligomers as Potential Targets for Alzheimer’s Diagnosis and Novel Drugs
por: Guzmán-Martinez, Leonardo, et al.
Publicado: (2013)

Doxycycline for Alzheimer’s Disease: Fighting β-Amyloid Oligomers and Neuroinflammation
por: Balducci, Claudia, et al.
Publicado: (2019)

Synaptic Disruption by Soluble Oligomers in Patients with Alzheimer’s and Parkinson’s Disease
por: Gutierrez, Berenice A., et al.
Publicado: (2022)

Editorial: Beta-Amyloid oligomer specific treatments for Alzheimer's disease
por: Hillen, Heinz
Publicado: (2023)

Disruption of Amyloid Plaques Integrity Affects the Soluble Oligomers Content from Alzheimer Disease Brains
por: Jimenez, Sebastian, et al.
Publicado: (2014)

Opposed Effects of Dityrosine Formation in Soluble and Aggregated α-Synuclein on Fibril Growth
por: Wördehoff, Michael M., et al.
Publicado: (2017)

The Aβ oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology
por: van Groen, Thomas, et al.
Publicado: (2017)

Mechanisms of Hybrid Oligomer Formation in the Pathogenesis of Combined Alzheimer's and Parkinson's Diseases
por: Tsigelny, Igor F., et al.
Publicado: (2008)

Amyloid-β oligomers set fire to inflammasomes and induce Alzheimer's pathology
por: Salminen, Antero, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_5om6d35cv2vr3gtkedskrmi2at